Omega-3 Fatty Acids for Rheumatoid Arthritis

Rheumatoid arthritis is one of the oldest and best-supported uses of fish oil, with a specific and modest claim: less joint tenderness and morning stiffness, and in some trials a reduced need for NSAIDs.

Meta-analyses of randomised trials report reductions in tender joint count, morning stiffness duration and analgesic use with high-dose EPA and DHA over three to six months. Doses used are substantial - typically 2.7 g or more of combined EPA and DHA daily - and the effect appears slowly. What omega-3 does not do is alter disease activity in the way that matters most. It does not prevent joint erosion or radiographic progression, and it is not a substitute for disease-modifying antirheumatic drugs. Untreated rheumatoid arthritis causes permanent joint destruction.

Rheumatoid arthritis is driven by autoimmune synovial inflammation, with the inflammatory cascade partly built on arachidonic-acid-derived eicosanoids: series-2 prostaglandins and series-4 leukotrienes, notably leukotriene B4, a potent neutrophil chemoattractant found in high concentration in rheumatoid synovial fluid.

EPA competes with arachidonic acid for cyclooxygenase and lipoxygenase, producing series-3 prostaglandins and series-5 leukotrienes that are markedly less inflammatory. EPA and DHA also give rise to resolvins, protectins and maresins, which actively terminate inflammation rather than merely suppressing it, and they reduce NF-kB-driven cytokine production including TNF-alpha and IL-1. This is symptom-level immunomodulation, not immune reprogramming. Autoantibody production and the underlying autoimmune process continue, which is exactly why the joint damage trajectory is unchanged.

Effective doses here are high - considerably above general supplementation.

There are currently no studies linked to this pairing in our library, so no study list is shown.

Multiple meta-analyses of randomised placebo-controlled trials report statistically significant reductions in tender joint count, morning stiffness and NSAID consumption with high-dose fish oil in rheumatoid arthritis. The consistency across decades of independent trials is a genuine strength, and reduced analgesic requirement is a patient-relevant endpoint. Against that: effect sizes are modest, many trials predate modern treat-to-target DMARD and biologic therapy, doses and formulations vary, blinding is imperfect because fish oil is identifiable by taste, and radiographic progression endpoints show no benefit.

At 3 g daily, gastrointestinal upset, reflux and fishy repeat are common enough to matter. Taking doses split across meals, using enteric-coated or emulsified products, or freezing capsules all help. Choose oils with low peroxide values, since oxidised oil is pro-inflammatory.

Rheumatoid arthritis requires specialist management. Worsening joint swelling, new joint involvement, fever, weight loss, breathlessness or eye inflammation need prompt review, since extra-articular disease and drug toxicity both present this way. Tell your rheumatology team about supplementation so it is factored into bleeding and interaction assessments.

The important interactions involve bleeding and standard rheumatology drugs.

No studies are currently linked to this pairing, so no reference list is available. This section will populate as evidence is added to the library.